Positive Mid-Year Results from AIM ImmunoTech
AIM ImmunoTech Inc. (NYSE American: AIM) has recently shared encouraging findings from ongoing clinical research focused on Ampligen® (rintatolimod), a drug under investigation for treating pancreatic cancer. The data stems from a Phase 2 study, which is the result of collaboration with AstraZeneca, assessing the effectiveness of Ampligen combined with AstraZeneca's Imfinzi® (durvalumab).
Overview of the DURIPANC Study
The DURIPANC study is an open-label Phase 2 trial that aims to address an unmet medical need in the treatment of pancreatic cancer patients who have stable disease following FOLFIRINOX regimen. Currently, 14 participants have been enrolled, with the total expected recruitment number set at 25. This trial focuses on determining the clinical benefit rate while also evaluating overall survival (OS) and progression-free survival (PFS) among other factors.
Initial Patient Feedback
Dr. Casper van Eijck from Erasmus Medical Center expressed optimism about the early outcomes of the trial. The preliminary results reveal that the Ampligen and durvalumab combination is generally well tolerated, presenting a positive safety profile in a challenging treatment landscape. This feedback is particularly significant given the historical challenges in achieving improved outcomes for this patient population.
Key Findings from the Trial
The DURIPANC mid-year report highlights some compelling early findings:
- No significant toxicity observed with the combination therapy, indicating a strong safety profile.
- Approximately 21% of the patients experienced progression-free survival exceeding six months, with an additional 21% who have yet to progress further in their treatment.
- 64% of eligible patients demonstrated overall survival beyond six months, surpassing typical expectations for such a treatment scenario.
Going Forward with Ampligen
According to AIM ImmunoTech CEO Thomas K. Equels, the data being gathered through Ampligen as an ongoing monotherapy has shown highly positive results compared to current treatment options. Given this foundational success, the DURIPANC study is expected to reveal further benefits of using Ampligen in conjunction with durvalumab for maintenance therapy in pancreatic cancer cases. He anticipates that imminent immune-monitoring data will uncover vital insights into the therapeutic mechanisms at play and help identify the most promising patient profiles for this treatment.
Extensive Background on Ampligen
AIM ImmunoTech has dedicated several years to exploring Ampligen as a treatment option for pancreatic cancer. Since being authorized for compassionate use in the Netherlands in 2017, over 50 pancreatic cancer patients have benefited from Ampligen as an immuno-oncology monotherapy.
Research Publications and Findings
The outcomes from multiple detailed analyses, made possible through the extensive use of Ampligen, have been documented in various abstracts and peer-reviewed publications. These analyses detail the drug's potential for enhancing immune responses as seen through increased peripheral B cells and relevant patient survival rates.
AIM ImmunoTech's Commitment
Recognizing the significance of their findings, AIM has formulated an Intellectual Property strategy concerning Ampligen's use in pancreatic cancer, which includes securing a U.S. patent that lasts until 2039 and obtaining orphan drug designations in critical markets including the United States and European Union. These protections are vital for ensuring that AIM can safeguard its innovations in developing potent therapies tailored for pancreatic cancer patients.
About the Company
AIM ImmunoTech Inc. is a dedicated immuno-pharmaceutical entity committed to innovating therapeutic solutions for various cancers, immune disorders, and viral infections, including COVID-19. The company's flagship drug, Ampligen® (rintatolimod), acts as a robust immuno-modulator, which is currently in clinical trials targeting significant global health challenges.
To stay updated on AIM ImmunoTech’s progress and research findings, interested parties can follow the company’s ongoing developments through various platforms.
Frequently Asked Questions
What is the DURIPANC study focused on?
The DURIPANC study examines the effectiveness of Ampligen in conjunction with durvalumab for treating pancreatic cancer patients after FOLFIRINOX therapy.
How many patients are currently enrolled in the study?
As of the latest report, 14 patients have been successfully enrolled in the DURIPANC study.
What safety outcomes have been reported?
The combination therapy showcased no significant toxicity, indicating its overall safety for patients.
What are the survival rates reported?
The study reported an overall survival rate greater than six months in 64% of the eligible patients.
What future prospects does AIM have for its cancer therapies?
AIM plans to leverage the promising data from these trials to refine their therapies and conduct further investigations into the combined effects of Ampligen and other treatments.
